{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:28:51Z","timestamp":1793287731572,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10620-025-09052-5","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:33:41Z","timestamp":1744799621000},"page":"2786-2793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry Study"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4197-0950","authenticated-orcid":false,"given":"Dorien","family":"Oomkens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-0381","authenticated-orcid":false,"given":"Zlatan","family":"Mujagic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-9201","authenticated-orcid":false,"given":"Annemarie","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-5431","authenticated-orcid":false,"given":"Andrea","family":"van der Meulen-de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6989-5226","authenticated-orcid":false,"given":"Tessa","family":"Straatmijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4975-9945","authenticated-orcid":false,"given":"Mark","family":"L\u00f6wenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7672-2483","authenticated-orcid":false,"given":"Sander","family":"van der Marel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-9393","authenticated-orcid":false,"given":"Rachel","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-9995","authenticated-orcid":false,"given":"Alexander","family":"Bodelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2451-1809","authenticated-orcid":false,"given":"Fiona","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-7677","authenticated-orcid":false,"given":"Marijn","family":"Visschedijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-9376","authenticated-orcid":false,"given":"Marjolijn","family":"Duijvestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Initiative on Crohn and Colitis (ICC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad","family":"van Bodegraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Bouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"van Dop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"Festen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Groenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Horjus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindia","family":"Jharap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Leemreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Maljaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nofel","family":"Mahmmod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wout","family":"Mares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liekele","family":"Oostenbrug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Pierik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel","family":"Ponsioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"R\u00f6mkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Russel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jael","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Stokkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Voorneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"van der Voorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinse","family":"Weersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"9052_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12876-023-02692-9","volume":"23","author":"SA Lautenschlager","year":"2023","unstructured":"Lautenschlager SA, Barry MP, Rogler G, Biedermann L, Schreiner P, Siebenhuner AR et al. Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study. BMC Gastroenterol. 2023;23:71. https:\/\/doi.org\/10.1186\/s12876-023-02692-9.","journal-title":"BMC Gastroenterol."},{"key":"9052_CR2","doi-asserted-by":"publisher","first-page":"832","DOI":"10.14309\/ajg.0000000000000608","volume":"115","author":"JJ Rozich","year":"2020","unstructured":"Rozich JJ, Holmer A, Singh S. Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2020;115:832\u2013840. https:\/\/doi.org\/10.14309\/ajg.0000000000000608.","journal-title":"Am J Gastroenterol."},{"key":"9052_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","volume":"14","author":"S Singh","year":"2017","unstructured":"Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110\u2013121. https:\/\/doi.org\/10.1038\/nrgastro.2016.181.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"9052_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/s0140-6736(14)60460-8","volume":"384","author":"M Ng","year":"2014","unstructured":"Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014;384:766\u2013781. https:\/\/doi.org\/10.1016\/s0140-6736(14)60460-8.","journal-title":"The Lancet."},{"key":"9052_CR5","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.3748\/wjg.v22.i35.7868","volume":"22","author":"JW Harper","year":"2016","unstructured":"Harper JW, Zisman TL. Interaction of obesity and inflammatory bowel disease. World J Gastroenterol. 2016;22:7868\u20137881. https:\/\/doi.org\/10.3748\/wjg.v22.i35.7868.","journal-title":"World J Gastroenterol."},{"key":"9052_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11894-022-00840-x","volume":"24","author":"NS Khakoo","year":"2022","unstructured":"Khakoo NS, Ioannou S, Khakoo NS, Vedantam S, Pearlman M. Impact of Obesity on Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2022;24:26\u201336. https:\/\/doi.org\/10.1007\/s11894-022-00840-x.","journal-title":"Curr Gastroenterol Rep."},{"key":"9052_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/sjg.sjg_30_21","volume":"27","author":"AM Johnson","year":"2021","unstructured":"Johnson AM, Loftus EV. Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD. Saudi J Gastroenterol. 2021;27:183\u2013190. https:\/\/doi.org\/10.4103\/sjg.sjg_30_21.","journal-title":"Saudi J Gastroenterol."},{"key":"9052_CR8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002741","author":"DR Ebach","year":"2024","unstructured":"Ebach DR, Jester TW, Galanko JA, Firestine AM, Ammoury R, Cabrera J et al. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn\u2019s Disease. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000002741.","journal-title":"Am J Gastroenterol."},{"key":"9052_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","volume":"35","author":"E Bultman","year":"2012","unstructured":"Bultman E, de Haar C, van Liere-Baron A, Verhoog H, West RL, Kuipers EJ et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn\u2019s disease patients. Aliment Pharmacol Ther. 2012;35:335\u2013341. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04946.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"9052_CR10","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/apt.14665","volume":"47","author":"S Kurnool","year":"2018","unstructured":"Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, VandeCasteele N et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1472\u20131479. https:\/\/doi.org\/10.1111\/apt.14665.","journal-title":"Aliment Pharmacol Ther."},{"key":"9052_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41395-018-0104-x","volume":"113","author":"S Singh","year":"2018","unstructured":"Singh S, Proudfoot J, Xu R, Sandborn WJ. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2018;113:883\u2013889. https:\/\/doi.org\/10.1038\/s41395-018-0104-x.","journal-title":"Am J Gastroenterol."},{"key":"9052_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.20524\/aog.2022.0699","volume":"35","author":"LJ Levine","year":"2022","unstructured":"Levine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Ann Gastroenterol. 2022;35:275\u2013280. https:\/\/doi.org\/10.20524\/aog.2022.0699.","journal-title":"Ann Gastroenterol."},{"key":"9052_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/ibd\/izaa214","volume":"27","author":"ECL Wong","year":"2021","unstructured":"Wong ECL, Marshall JK, Reinisch W, Narula N. Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn\u2019s Disease: A Post Hoc Analysis of the IM-UNITI Trial. Inflamm Bowel Dis. 2021;27:848\u2013854. https:\/\/doi.org\/10.1093\/ibd\/izaa214.","journal-title":"Inflamm Bowel Dis."},{"key":"9052_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120780","author":"J Bilski","year":"2019","unstructured":"Bilski J, Mazur-Bialy A, Wojcik D, Surmiak M, Magierowski M, Sliwowski Z et al. Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases. Biomolecules. 2019. https:\/\/doi.org\/10.3390\/biom9120780.","journal-title":"Biomolecules."},{"key":"9052_CR15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/Mib.0000000000000212","volume":"20","author":"I Dotan","year":"2014","unstructured":"Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L et al. Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study. Inflammatory Bowel Diseases. 2014;20:2247\u20132259. https:\/\/doi.org\/10.1097\/Mib.0000000000000212.","journal-title":"Inflammatory Bowel Diseases."},{"key":"9052_CR16","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1172\/JCI117936","volume":"95","author":"GS Hotamisligil","year":"1995","unstructured":"Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409\u20132415. https:\/\/doi.org\/10.1172\/JCI117936.","journal-title":"J Clin Invest."},{"key":"9052_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2023.06.036","volume":"165","author":"AJ Yarur","year":"2023","unstructured":"Yarur AJ, Bruss A, Moosreiner A, Beniwal-Patel P, Nunez L, Berens B et al. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study. Gastroenterology. 2023;165:963\u201375 e5. https:\/\/doi.org\/10.1053\/j.gastro.2023.06.036.","journal-title":"Gastroenterology."},{"key":"9052_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/apt.15730","volume":"51","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, Savelkoul E, Gabriels RY, Simsek M, Dijkstra G, Pierik MJ et al. A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2020;51:1076\u20131086. https:\/\/doi.org\/10.1111\/apt.15730.","journal-title":"Aliment Pharmacol Ther."},{"key":"9052_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cpt.1712","volume":"107","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK et al. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. Clin Pharmacol Ther. 2020;107:1189\u20131199. https:\/\/doi.org\/10.1002\/cpt.1712.","journal-title":"Clin Pharmacol Ther."},{"key":"9052_CR20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/apt.17153","volume":"56","author":"A Volkers","year":"2022","unstructured":"Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F et al. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;56:1044\u20131054. https:\/\/doi.org\/10.1111\/apt.17153.","journal-title":"Aliment Pharmacol Ther."},{"key":"9052_CR21","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/ecco-jcc\/jjab081","volume":"15","author":"T Straatmijer","year":"2021","unstructured":"Straatmijer T, Biemans VBC, Hoentjen F, de Boer NKH, Bodelier AGL, Dijkstra G et al. Ustekinuma b for Crohn\u2019s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2021;15:1920\u20131930. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab081.","journal-title":"J Crohns Colitis."},{"key":"9052_CR22","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.15689","volume":"51","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51:880\u2013888. https:\/\/doi.org\/10.1111\/apt.15689.","journal-title":"Aliment Pharmacol Ther."},{"key":"9052_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pcad.2022.11.013","volume":"78","author":"AW Tutor","year":"2023","unstructured":"Tutor AW, Lavie CJ, Kachur S, Milani RV, Ventura HO. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2023;78:2\u201310. https:\/\/doi.org\/10.1016\/j.pcad.2022.11.013.","journal-title":"Prog Cardiovasc Dis."},{"key":"9052_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00384-014-2051-3","volume":"30","author":"D Stabroth-Akil","year":"2015","unstructured":"Stabroth-Akil D, Leifeld L, Pfutzer R, Morgenstern J, Kruis W. The effect of body weight on the severity and clinical course of ulcerative colitis. Int J Colorectal Dis. 2015;30:237\u2013242. https:\/\/doi.org\/10.1007\/s00384-014-2051-3.","journal-title":"Int J Colorectal Dis."},{"key":"9052_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s10620-009-0846-9","volume":"55","author":"MH Holtmann","year":"2010","unstructured":"Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O et al. Significant differences between Crohn\u2019s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci. 2010;55:1066\u20131078. https:\/\/doi.org\/10.1007\/s10620-009-0846-9.","journal-title":"Dig Dis Sci."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09052-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09052-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T06:47:15Z","timestamp":1755672435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09052-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["9052"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09052-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DO: none. ZM: reports grants from ZonMw, MLDS, Niels Stensen Fellowship, and Galapagos, and has served as speaker for Galapagos, adviser for Johnson and Johnson, Pfizer, Galapagos, AbbVie and Lilly. ACV: advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos; research grants from Takeda, Janssen, and Pfizer, outside submitted work. AEvdM: speaker for Galapagos, Janssen-Cilag, Takeda, Tramedico; research grants from Cablon, Galapagos, Nestle, Norgine, and ZonMW. TS: none. ML: Abbvie, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen-Cilag, Johnson & Johnson, Medtronic, Pfizer, Takeda, Tillotts. Central reader for Alimentiv. Grants received from Galapagos, Pfizer and ZonMW. SvdM: advisory boards for Pfizer, Abbvie, and Janssen, outside submitted work; IBD documentary funded by Takeda; podcast funded by Janssen. RW: advisory board or speaker for Janssen, Abbvie, and Pfizer. AB: advisory board of Takeda, Abbvie, and Janssen, outside submitted work. FvS: adviser and\/or speaker for Takeda, Galapagos, Dr. Falk, Lilly and Janssen-Cilag and received an unrestricted grant from Takeda. MCV: speaker fees from Janssen-Cilag, Galapagos, and Ferring B.V. MD: advisory fees from Echo Pharma and Robarts Clinical Trials, Inc.; speaker fees from Janssen, Merck & Co., Inc., Pfizer, Takeda, and Tillotts Pharma; nonfinancial support from Dr. Falk Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed and approved by the Committee on Research Involving Human Subjects at the Radboudumc [institutional review board: 4076], and all procedures adhered to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants in the ICC registry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}